Longfellow Sells Hatch Life Sciences Building in LIC for $87M

Why this matters

Longfellow’s sale of its inaugural New York City life sciences asset at a discount signals a notable recalibration in institutional appetite and pricing for lab space in secondary urban markets. The transaction underscores growing caution among capital providers amid a broader tightening in CRE financing, particularly for specialized property types with complex leasing and operational profiles. Life sciences real estate has been a favored sector for private-equity and fund capital seeking defensive growth, but this deal suggests that even established developers face challenges in achieving premium pricing outside core biotech hubs. The discount points to either softening fundamentals in Long Island City’s lab market or heightened risk premia demanded by buyers, reflecting concerns over tenant credit, lease rollover, or development pipeline saturation. For allocators, the sale highlights the importance of granular market selection and underwriting discipline in life sciences exposure, as well as the potential for repricing in assets once considered insulated from broader CRE volatility. It also illustrates how capital flows are increasingly bifurcated between trophy assets in gateway markets and secondary locations where liquidity and pricing remain more vulnerable.

Editorial analysis · AI-assisted

On the RET wire

• The 59th New York story tracked on the wire in August 2026. All New York coverage →

Computed from Real Estate Trail’s own tracked coverage

External link. Real Estate Trail does not republish source content.